Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hibor in COVID-19 Pneumonia
NCT04604327Phase 3Unknown
- Sponsor
- Universidad de Navarra
- Start
- Oct 2020
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bemiparin in COVID-19 pneumonia, sponsored by Universidad de Navarra. Primary endpoint: Clinical deterioration at 10 days. Status: unknown.
02
Drugs
bemiparin
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04604327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04604327.